Law360, New York (November 03, 2010, 1:22 PM ET) -- The judge hearing one of the bellwether cases in multidistrict litigation alleging the osteoporosis drug Fosamax caused a bone-rotting condition in the plaintiff’s jaw has elected to bar the plaintiff from introducing evidence of Merck & Co.'s conduct after March 31, 2003.
Judge John F. Keenan in the U.S. District Court for the Southern District of New York on Oct. 27 also said he would exclude expert testimony from one doctor and evidence concerning risks of Fosamax use other than osteonecrosis of the jaw.
He denied...
Fosamax Judge Restricts Bellwether Trial Evidence
To view the full article, take a free trial now.
